$PLX rises 13% following an interview with Dror Bashan, CEO of BizPortal TV . In which he explains why he raised capital that caused the stock to fall, marks the drug for Fabry as the main growth engine of Protelix and defines two important events that could be the company's turning point. Protalix, which has already developed a drug and previously received FDA approval, will this time be able to both get the FDA and be successful in the business world? bizportal.co.il/capitalmark...
1
1
1 Like